Cargando…
Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab
BACKGROUND: Therapeutic antibodies targeting the IGF1R have shown diverse efficacy and safety signals in oncology clinical trials. The success of these agents as future human therapeutics depends on understanding the specific mechanisms by which these antibodies target IGF1R signaling. METHODOLOGY/P...
Autores principales: | Calzone, Frank J., Cajulis, Elaina, Chung, Young-Ah, Tsai, Mei- Mei, Mitchell, Petia, Lu, John, Chen, Ching, Sun, Jilin, Radinsky, Robert, Kendall, Richard, Beltran, Pedro J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3562316/ https://www.ncbi.nlm.nih.gov/pubmed/23383308 http://dx.doi.org/10.1371/journal.pone.0055135 |
Ejemplares similares
-
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017) -
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
por: Shulman, David S., et al.
Publicado: (2023) -
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
por: Yee, Douglas, et al.
Publicado: (2021) -
HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells
por: Wilson, Cindy A, et al.
Publicado: (2005) -
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors
por: Murakami, Haruyasu, et al.
Publicado: (2012)